PhaseBio Pharmaceuticals Repayment/Issuance of Debt (Net)

Repayment/Issuance of Debt (Net) of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Repayment/Issuance of Debt (Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Repayment/Issuance of Debt (Net) for the quarter ending June 29, 2021 was $-1.36 Million (a -0.07% decrease compared to previous quarter)
  • Year-over-year quarterly Repayment/Issuance of Debt (Net) decreased by -0.07%
  • Annual Repayment/Issuance of Debt (Net) for 2020 was $-2.73 Million (a -138.92% decrease from previous year)
  • Annual Repayment/Issuance of Debt (Net) for 2019 was $7.01 Million (a 75.37% increase from previous year)
  • Annual Repayment/Issuance of Debt (Net) for 2018 was $4 Million (a -78.0% decrease from previous year)
  • Twelve month Repayment/Issuance of Debt (Net) ending June 29, 2021 was $-5.45 Million (a -700.0% decrease compared to previous quarter)
  • Twelve month trailing Repayment/Issuance of Debt (Net) decreased by -189.28% year-over-year
Trailing Repayment/Issuance of Debt (Net) for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$-5.45 Million $909 Thousand $2.27 Million $6.11 Million
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Repayment/Issuance of Debt (Net) of PhaseBio Pharmaceuticals

Most recent Repayment/Issuance of Debt (Net)of PHAS including historical data for past 10 years.

Interactive Chart of Repayment/Issuance of Debt (Net) of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Repayment/Issuance of Debt (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-1.36 $-1.36
2020 $-1.36 $-1.36 $-2.73
2019 $5.0 $0.0 $2.47 $-0.32 $7.01
2018 $0.0 $2.0 $2.0 $4.0
2017 $11.56 $6.6 $18.16

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.